|
1
|
Sung H, Ferlay J, Siegel RL, Laversanne M,
Soerjomataram I, Jemal A and Bray F: Global cancer statistics 2020:
GLOBOCAN estimates of incidence and mortality worldwide for 36
cancers in 185 countries. CA Cancer J Clin. 71:209–249. 2021.
View Article : Google Scholar : PubMed/NCBI
|
|
2
|
Wang Y, Liu Y, Liu Y, Zhou W, Wang H, Wan
G, Sun D, Zhang N and Wang Y: A polymeric prodrug of cisplatin
based on pullulan for the targeted therapy against hepatocellular
carcinoma. Int J Pharm. 483:89–100. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
3
|
El Dika I, Makki I and Abou-Alfa GK:
Hepatocellular carcinoma, novel therapies on the horizon. Chin Clin
Oncol. 10:122021. View Article : Google Scholar : PubMed/NCBI
|
|
4
|
Anwanwan D, Singh SK, Singh S, Saikam V
and Singh R: Challenges in liver cancer and possible treatment
approaches. Biochim Biophys Acta Rev Cancer. 1873:1883142020.
View Article : Google Scholar : PubMed/NCBI
|
|
5
|
Gurzu S, Kobori L, Fodor D and Jung I:
Epithelial mesenchymal and endothelial mesenchymal transitions in
hepatocellular carcinoma: A review. Biomed Res Int.
2019:29625802019. View Article : Google Scholar : PubMed/NCBI
|
|
6
|
Demir T, Lee SS and Kaseb AO: Systemic
therapy of liver cancer. Adv Cancer Res. 149:257–294. 2021.
View Article : Google Scholar : PubMed/NCBI
|
|
7
|
Dutta S, Mahalanobish S, Saha S, Ghosh S
and Sil PC: Natural products: An upcoming therapeutic approach to
cancer. Food Chem Toxicol. 128:240–255. 2019. View Article : Google Scholar : PubMed/NCBI
|
|
8
|
Ghosh S: Cisplatin: The first metal based
anticancer drug. Bioorg Chem. 88:1029252019. View Article : Google Scholar : PubMed/NCBI
|
|
9
|
Fuertes MA, Alonso C and Pérez JM:
Biochemical modulation of cisplatin mechanisms of action:
Enhancement of antitumor activity and circumvention of drug
resistance. Chem Rev. 103:645–662. 2003. View Article : Google Scholar : PubMed/NCBI
|
|
10
|
Oun R and Rowan E: Cisplatin induced
arrhythmia; electrolyte imbalance or disturbance of the SA node?
Eur J Pharmacol. 811:125–128. 2017. View Article : Google Scholar : PubMed/NCBI
|
|
11
|
Pabla N and Dong Z: Cisplatin
nephrotoxicity: Mechanisms and renoprotective strategies. Kidney
Int. 73:994–1007. 2008. View Article : Google Scholar : PubMed/NCBI
|
|
12
|
Santos NAGD, Ferreira RS and Santos ACD:
Overview of cisplatin-induced neurotoxicity and ototoxicity, and
the protective agents. Food Chem Toxicol. 136:1110792020.
View Article : Google Scholar : PubMed/NCBI
|
|
13
|
Astolfi L, Ghiselli S, Guaran V, Chicca M,
Simoni E, Olivetto E, Lelli G and Martini A: Correlation of adverse
effects of cisplatin administration in patients affected by solid
tumours: A retrospective evaluation. Oncol Rep. 29:1285–1292. 2013.
View Article : Google Scholar : PubMed/NCBI
|
|
14
|
Miller LH and Su X: Artemisinin: Discovery
from the Chinese herbal garden. Cell. 146:855–858. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
15
|
Ma N, Zhang Z, Liao F, Jiang T and Tu Y:
The birth of artemisinin. Pharmacol Ther. 216:1076582020.
View Article : Google Scholar : PubMed/NCBI
|
|
16
|
Haynes RK: From artemisinin to new
artemisinin antimalarials: Biosynthesis, extraction, old and new
derivatives, stereochemistry and medicinal chemistry requirements.
Curr Top Med Chem. 6:509–537. 2006. View Article : Google Scholar : PubMed/NCBI
|
|
17
|
Dai X, Zhang X, Chen W, Chen Y, Zhang Q,
Mo S and Lu J: Dihydroartemisinin: A potential natural anticancer
drug. Int J Biol Sci. 17:603–622. 2021. View Article : Google Scholar : PubMed/NCBI
|
|
18
|
Chen X, He LY, Lai S and He Y:
Dihydroartemisinin inhibits the migration of esophageal cancer
cells by inducing autophagy. Oncol Lett. 20:942020. View Article : Google Scholar : PubMed/NCBI
|
|
19
|
Wu L, Pang Y, Qin G, Xi G, Wu S, Wang X
and Chen T: Farnesylthiosalicylic acid sensitizes hepatocarcinoma
cells to artemisinin derivatives. PLoS One. 12:e01718402017.
View Article : Google Scholar : PubMed/NCBI
|
|
20
|
Zhang R, Niu Y and Zhou Y: Increase the
cisplatin cytotoxicity and cisplatin-induced DNA damage in HepG2
cells by XRCC1 abrogation related mechanisms. Toxicol Lett.
192:108–114. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
21
|
Raudenska M, Balvan J, Fojtu M, Gumulec J
and Masarik M: Unexpected therapeutic effects of cisplatin.
Metallomics. 11:1182–1199. 2019. View Article : Google Scholar : PubMed/NCBI
|
|
22
|
Kiss RC, Xia F and Acklin S: Targeting DNA
damage response and repair to enhance therapeutic index in
cisplatin-based cancer treatment. Int J Mol Sci. 22:81992021.
View Article : Google Scholar : PubMed/NCBI
|
|
23
|
Sun Y, Jiang W, Lu W, Song M, Liu K, Chen
P, Chang A, Ling J, Chiao PJ, Hu Y and Huang P: Identification of
cisplatin sensitizers through high-throughput combinatorial
screening. Int J Oncol. 53:1237–1246. 2018.PubMed/NCBI
|
|
24
|
Liu L, Fan J, Ai G, Liu J, Luo N, Li C and
Cheng Z: Berberine in combination with cisplatin induces
necroptosis and apoptosis in ovarian cancer cells. Biol Res.
52:372019. View Article : Google Scholar : PubMed/NCBI
|
|
25
|
Rejhová A, Opattová A, Čumová A, Slíva D
and Vodička P: Natural compounds and combination therapy in
colorectal cancer treatment. Eur J Med Chem. 144:582–594. 2018.
View Article : Google Scholar : PubMed/NCBI
|
|
26
|
Abe K, Yamamoto N, Hayashi K, Takeuchi A
and Tsuchiya H: Caffeine citrate enhanced cisplatin antitumor
effects in osteosarcoma and fibrosarcoma in vitro and in vivo. BMC
Cancer. 19:6892019. View Article : Google Scholar : PubMed/NCBI
|
|
27
|
Tu Y: The discovery of artemisinin
(qinghaosu) and gifts from Chinese medicine. Nat Med. 17:1217–1220.
2011. View
Article : Google Scholar : PubMed/NCBI
|
|
28
|
Angus B: Novel anti-malarial combinations
and their toxicity. Expert Rev Clin Pharmacol. 7:299–316. 2014.
View Article : Google Scholar : PubMed/NCBI
|
|
29
|
Wan X, Zhong H, Pan W, Li Y, Chen Y, Li N
and Tang B: Programmed release of dihydroartemisinin for
synergistic cancer therapy using a CaCO3 mineralized
metal-organic framework. Angew Chem Int Ed Engl. 58:14134–14139.
2019. View Article : Google Scholar : PubMed/NCBI
|
|
30
|
Im E, Yeo C, Lee HJ and Lee EO:
Dihydroartemisinin induced caspase-dependent apoptosis through
inhibiting the specificity protein 1 pathway in hepatocellular
carcinoma SK-Hep-1 cells. Life Sci. 192:286–292. 2018. View Article : Google Scholar : PubMed/NCBI
|
|
31
|
Li Q, Ma Q, Cheng J, Zhou X, Pu W, Zhong X
and Guo X: Dihydroartemisinin as a sensitizing agent in cancer
therapies. Onco Targets Ther. 14:2563–2573. 2021. View Article : Google Scholar : PubMed/NCBI
|
|
32
|
Tai X, Cai XB, Zhang Z and Wei R: In
vitro and in vivo inhibition of tumor cell viability by
combined dihydroartemisinin and doxorubicin treatment, and the
underlying mechanism. Oncol Lett. 12:3701–3706. 2016. View Article : Google Scholar : PubMed/NCBI
|
|
33
|
Jin H, Jiang AY, Wang H, Cao Y, Wu Y and
Jiang XF: Dihydroartemisinin and gefitinib synergistically inhibit
NSCLC cell growth and promote apoptosis via the Akt/mTOR/STAT3
pathway. Mol Med Rep. 16:3475–3481. 2017. View Article : Google Scholar : PubMed/NCBI
|
|
34
|
Dasari S, Njiki S, Mbemi A, Yedjou CG and
Tchounwou PB: Pharmacological effects of cisplatin combination with
natural products in cancer chemotherapy. Int J Mol Sci.
23:15322022. View Article : Google Scholar : PubMed/NCBI
|
|
35
|
Qi L, Luo Q, Zhang Y, Jia F, Zhao Y and
Wang F: Advances in toxicological research of the anticancer drug
cisplatin. Chem Res Toxicol. 32:1469–1486. 2019. View Article : Google Scholar : PubMed/NCBI
|
|
36
|
Makovec T: Cisplatin and beyond: Molecular
mechanisms of action and drug resistance development in cancer
chemotherapy. Radiol Oncol. 53:148–158. 2019. View Article : Google Scholar : PubMed/NCBI
|
|
37
|
Zhou J, Kang Y, Chen L, Wang H, Liu J,
Zeng S and Yu L: The drug-resistance mechanisms of five
platinum-based antitumor agents. Front Pharmacol. 11:3432020.
View Article : Google Scholar : PubMed/NCBI
|
|
38
|
Mao H, Gu H, Qu X, Sun J, Song B, Gao W,
Liu J and Shao Q: Involvement of the mitochondrial pathway and
Bim/Bcl-2 balance in dihydroartemisinin-induced apoptosis in human
breast cancer in vitro. Int J Mol Med. 31:213–218. 2013.
View Article : Google Scholar : PubMed/NCBI
|
|
39
|
Hu YJ, Zhang JY, Luo Q, Xu JR, Yan Y, Mu
LM, Bai J and Lu WL: Nanostructured dihydroartemisinin plus
epirubicin liposomes enhance treatment efficacy of breast cancer by
inducing autophagy and apoptosis. Nanomaterials (Basel). 8:8042018.
View Article : Google Scholar : PubMed/NCBI
|
|
40
|
Wang Y, Liu Y, Xiang L, Han L, Yao X, Hu Y
and Wu F: Cyclin D1b induces changes in the macrophage phenotype
resulting in promotion of tumor metastasis. Exp Biol Med (Maywood).
246:2559–2569. 2021. View Article : Google Scholar : PubMed/NCBI
|
|
41
|
Bao Y, Zhang Y, Lu Y, Guo H, Dong Z, Chen
Q, Zhang X, Shen W, Chen W and Wang X: Overexpression of microRNA-9
enhances cisplatin sensitivity in hepatocellular carcinoma by
regulating EIF5A2-mediated epithelial-mesenchymal transition. Int J
Biol Sci. 16:827–837. 2020. View Article : Google Scholar : PubMed/NCBI
|
|
42
|
Du B and Shim JS: Targeting
epithelial-mesenchymal transition (EMT) to overcome drug resistance
in cancer. Molecules. 21:9652016. View Article : Google Scholar : PubMed/NCBI
|
|
43
|
Pastushenko I and Blanpain C: EMT
transition states during tumor progression and metastasis. Trends
Cell Biol. 29:212–226. 2019. View Article : Google Scholar : PubMed/NCBI
|
